The goal of this observational study is to test a protocol of personalized medicine in routine clinical practice in people with type 2 diabetes (T2DM) treated with multiple dose insulin injections (MDI).

The main question[s] it aims to answer are:

• Are c-peptide titers and B-cell autoimmunity useful to help the decision of suspending prandial insulin in patients with T2DM treated with MDI?

Participants will:

• Wear a continuous glucose monitor for 10-14 days
• Will be asked for a C-peptide and GAD antibody test (GADA)
• Will stop prandial insulin and switch to other diabetes treatments if needed if c-peptide is > 0.7 mmol/L and/or C-peptide is > 0.3 mmol/L and GADA are negative
• Will be followed-up by their GP in routine clinical practice
• Will be assessed after 6 months (CGM, HbA1c, quality of life (QoL)

An algorithm will be applied in which, depending on the presence/absence of pancreatic autoimmunity and the estimation of pancreatic reserve, the same treatment will be maintained and CGM (continuous glucose monitoring) will be initiated or the prandial insulin and the treatment will be adjusted following the main clinical guidelines.

Inclusion Criteria:

• Type 2 diabetes treated with multiple dose insulin therapy

Exclusion Criteria:

• Gestation or planning gestation in the following 12 months
• Glucocorticoid use for an acute condition
• Transient insulinisationt (less than 6 months)
• Any condition that prevents the patient or their caregiver from following up for 6 months
• Severe mental illness
• Drug or alcohol abuse

All the patients in our territory treated with multiple dose insulin therapy without exclusion criteria are elegible to participate.